Claims for Patent: 9,187,522

Summary for Patent: 9,187,522

Title:	GLP-1 receptor modulators
Abstract:	The invention relates to compounds that modulate the glucagon-like peptide 1 (GLP-1) receptor, methods of their synthesis, and methods of their therapeutic and/or prophylactic use. Such compounds are act as modulators or potentiators of GLP-1 receptor on their own, or with receptor ligands including GLP-1 peptides GLP-1(7-36) and GLP-1(9-36), or with peptide-based therapies, such as exenatide and liraglutide, and have the following general structure (where \"\" represents either or both the R and S form of the compound): ##STR00001## where A, B, C, Y.sub.1, Y.sub.2, Z, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, W.sub.1, n, p and q are as defined herein.
Inventor(s):	Boehm; Marcus F. (San Diego, CA), Martinborough; Esther (San Diego, CA), Moorjani; Manisha (San Diego, CA), Tamiya; Junko (Carlsbad, CA), Huang; Liming (San Diego, CA), Yeager; Adam R. (La Mesa, CA), Brahmachary; Enugurthi (San Diego, CA), Fowler; Thomas (Melton Mowbray, GB), Novak; Andrew (Nottingham, GB), Meghani; Premji (Leicestershire, GB), Knaggs; Michael (Burton-on-Trent, GB)
Assignee:	Receptos, Inc. (San Diego, CA)
Application Number:	14/296,907
Patent Claims:	1. A method of activation, potentiation, modulation or agonism of a glucagon-like peptide 1 receptor comprising contacting the receptor with an effective amount of a compound of having the structure of Formula I-R or I-S or a pharmaceutically acceptable isomer, enantiomer, racemate, salt, ester, prodrug, hydrate or solvate thereof: ##STR00527## wherein A is a 5-, 6- or 7-membered heteroaryl having one, two or three heteroatoms where each such heteroatom is independently selected from O, N, and S, and where any ring atom of such heteroaryl may be optionally substituted with one or more of R.sub.4; B is heterocyclyl or heterocyclylalkyl; C is aryl or arylalkyl; Y.sub.1 and Y.sub.2 are both null; Z is --C(O)--; each R.sub.1 is independently H or C.sub.1-4 alkyl; R.sub.2 is --O--R.sub.8, --N(R.sub.1)--SO.sub.2--R.sub.8, --NR.sub.41R.sub.42, --N(R.sub.1)--(CR.sub.aR.sub.b)--COOH, --N(R.sub.1)--(CR.sub.aR.sub.b).sub.m--CO--N(R.sub.1)-heterocyclyl, --N(R.sub.1)--(CR.sub.aR.sub.b).sub.m--CO--N(R.sub.1)(R.sub.7), or --N(R.sub.1)-- heterocyclyl, wherein R.sub.2 is not --OH or --NH.sub.2; each R.sub.3 and R.sub.4 is independently H, halo, alkyl, alkyl substituted with R.sub.31, alkoxy, haloalkyl, perhaloalkyl, haloalkoxy, perhaloalkoxy, aryl, heterocyclyl, --OH, --OR.sub.8, --CN, --NO.sub.2, --NR.sub.1R.sub.8, --C(O)R.sub.8, --C(O)NR.sub.1R.sub.8, --NR.sub.1C(O).sub.2R.sub.8, --SR.sub.8, --S(O)R.sub.8, --S(O).sub.2R.sub.8, --OS(O)R.sub.8, --S(O).sub.2NR.sub.1R.sub.8, --NR.sub.1S(O).sub.2R.sub.8, --(CR.sub.aR.sub.b).sub.mNR.sub.1R.sub.8, --(CR.sub.aR.sub.b).sub.mO(CR.sub.aR.sub.b).sub.mR.sub.8, --(CR.sub.aR.sub.b).sub.mNR.sub.1(CR.sub.aR.sub.b).sub.mR.sub.8 or --(CR.sub.aR.sub.b).sub.mNR.sub.1(CR.sub.aR.sub.b).sub.mCOOH; or any two R.sub.3 or R.sub.4 groups on the same carbon atom taken together form oxo; each R.sub.31 is independently H, halo, hydroxyl, --NR.sub.41R.sub.42, or alkoxy; each R.sub.40 is independently H or alkyl; each R.sub.41 and R.sub.42 is independently R.sub.40 or --(CH.sub.2).sub.n--COO--R.sub.40, --C(O)--R.sub.40, aryl, heteroaryl, or two taken together with the N atom to which they are attached can form a 3- to 7-membered heterocyclyl; W.sub.1 is null or -L.sub.1-(CR.sub.aR.sub.b).sub.m-L.sub.1-R.sub.6; each L.sub.1 is independently, from the proximal to distal end of the structure of Formula I-R or I-S, null, --C(O)O--, --S(O.sub.2)--, --S--, --N(R.sub.1)--C(O)--N(R.sub.1)--, --N(R.sub.1)--C(O)--O--, --(O)-- or --S(O.sub.2)--NR.sub.1--; each R.sub.a and R.sub.b is independently H, alkyl, alkoxy, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl, any of which alkyl, alkoxy, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl may be optionally (singly or multiply) substituted with R.sub.7 or --(CH.sub.2).sub.mC(O)OR.sub.40, --(CH.sub.2).sub.mOR.sub.40, --(CH.sub.2).sub.mSR.sub.40, --CH.sub.2).sub.mNR.sub.41R.sub.42, --(CH.sub.2).sub.mC(O)NR.sub.41R.sub.42; or any two R.sub.a and R.sub.b taken together with the carbon to which they are attached form a cycloalkyl or heterocyclyl; or R.sub.1 and any one of R.sub.a or R.sub.b taken together form heterocyclyl; R.sub.5 is R.sub.7, --(CH.sub.2).sub.m-L.sub.2-(CH.sub.2).sub.m--R.sub.7, or -(-L.sub.3(CR.sub.aR.sub.b).sub.r--).sub.s-L.sub.3-R.sub.7; R.sub.6 is H, alkyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, heterocycloalkyl, any of which may be optionally singly or multiply substituted with R.sub.7 or --(CH.sub.2).sub.m-L.sub.2-(CH.sub.2).sub.m--R.sub.7; R.sub.7 is H, halo, alkyl, haloalkyl, perhaloalkyl, alkoxy, --OH, --OR.sub.8, --CN, --NR.sub.1R.sub.8, --(CR.sub.aR.sub.b).sub.mO(CR.sub.aR.sub.b).sub.mR.sub.8, --NR.sub.1(CR.sub.aR.sub.b).sub.mR.sub.8, --C(O)R.sub.8, --NR.sub.1(CR.sub.aR.sub.b).sub.mCOOH, --NR.sub.1C(O)R.sub.8, --C(O)NR.sub.1R.sub.8, --SR.sub.8, --S(O)R.sub.8, --S(O).sub.2R.sub.8, --S(O).sub.2NR.sub.1R.sub.8, --NR.sub.1S(O).sub.2R.sub.8; or a ring moiety selected from cycloalkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl, where such ring moiety is optionally singly or multiply substituted with halo, --OH, --CN, alkyl, alkoxy, haloalkyl or perhaloalkyl; each R.sub.8 is independently H, alkyl, cycloalkyl or aryl; L.sub.2 is independently, from the proximal to distal end of the structure of Formula I-R or I-S, null, --O--, --OC(O)--, --NR.sub.1--, --C(O)NR.sub.1--, --N(R.sub.1)--C(O)--, --S(O.sub.2)--, --C(O)-- or --S(O.sub.2)--N(R.sub.1)--; each L.sub.3 is independently null, --O--, or --N(R.sub.1)-- each m is independently 0, 1, 2, 3, 4, 5 or 6; each n is independently 0 or 1 or 2; p is 0, 1, 2 or 3; q is 0, 1, 2 or 3; each r is independently 2, 3, or 4; and each s is independently 1, 2, 3, or 4. 2. A method of activation, potentiation, modulation or agonism of a glucagon-like peptide 1 (GLP-1) receptor in a subject in need thereof, said method comprising administering to said subject a compound having the structure of Formula I-R or I-S or a pharmaceutically acceptable isomer, enantiomer, racemate, salt, ester, prodrug, hydrate or solvate thereof: ##STR00528## wherein A is a 5, 6- or 7-membered heteroaryl having one, two or three heteroatoms where each such heteroatom is independently selected from O, N, and S, and where any ring atom of such heteroaryl may be optionally substituted with one or more of R.sub.4; B is heterocyclyl or heterocyclylalkyl; C is aryl or arylalkyl; Y.sub.1 and Y.sub.2 are both null; Z is --C(O)--; each R.sub.1 is independently H or C.sub.1-4alkyl; R.sub.2 is --O--R.sub.8, --N(R.sub.1)--SO.sub.2--R.sub.8, --NR.sub.41R.sub.42, --N(R.sub.1)--(CR.sub.aR.sub.b).sub.m--COOH, --N(R.sub.1)--(CR.sub.aR.sub.b).sub.m--CO--N(R.sub.1)-heterocyclyl, --N(R.sub.1)--(CR.sub.aR.sub.b).sub.m--CO--N(R.sub.1)(R.sub.7), or --N(R.sub.1)-heterocyclyl, wherein R.sub.2 is not --OH or --NH.sub.2; each R.sub.3 and R.sub.4 is independently H, halo, alkyl, alkyl substituted with R.sub.31, alkoxy, haloalkyl, perhaloalkyl, haloalkoxy, perhaloalkoxy, aryl, heterocyclyl, --OH, --OR.sub.8, --CN, --NO.sub.2, --NR.sub.1R.sub.8, --C(O)R.sub.8, --C(O)NR.sub.1R.sub.8, --NR.sub.1C(O)R.sub.8, --SR.sub.8, --S(O)R.sub.8, --S(O).sub.2R.sub.8, --OS(O).sub.2R.sub.8, --S(O).sub.2NR.sub.1R.sub.8, --NR.sub.1S(O).sub.2R.sub.8, --(CR.sub.aR.sub.b).sub.mNR.sub.1R.sub.8, --(CR.sub.aR.sub.b).sub.mO(CR.sub.aR.sub.b).sub.mR.sub.8, --(CR.sub.aR.sub.b).sub.mNR.sub.1(CR.sub.aR.sub.b).sub.mR.sub.8, or --(CR.sub.aR.sub.b).sub.mNR.sub.1(CR.sub.aR.sub.b).sub.mCOOH; or any two R.sub.3 or R.sub.4 groups on the same carbon atom taken together form oxo; each R.sub.31 is independently H, halo, hydroxyl, --NR.sub.41R.sub.42, or alkoxy; each R.sub.40 is independently H or alkyl; each R.sub.41 and R.sub.42 is independently R.sub.40 or --(CH.sub.2).sub.n--COO--R.sub.40, --C(O)--R.sub.40, aryl, heteroaryl, or two taken together with the N atom to which they are attached can form a 3- to 7-membered heterocyclyl; W.sub.1 is null or -L.sub.1-(CR.sub.aR.sub.b).sub.m-L.sub.1-R.sub.6; each L.sub.1 is independently, from the proximal to distal end of the structure of Formula I-R or I-S, null, --C(O)O--, --S(O.sub.2)--, --S--, --N(R.sub.1)--C(O)--N(R.sub.1)--, --N(R.sub.1)--C(O)--O--, --(O)-- or --S(O.sub.2)--NR.sub.1--; each R.sub.a and R.sub.b is independently H, alkyl, alkoxy, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl, any of which alkyl, alkoxy, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl may be optionally (singly or multiply) substituted with R.sub.7, or --(CH.sub.2).sub.mC(O)OR.sub.40, --(CH.sub.2).sub.mOR.sub.40, --(CH.sub.2).sub.mSR.sub.40, --(CH.sub.2).sub.mNR.sub.41R.sub.42, --(CH.sub.2).sub.mC(O)NR.sub.41R.sub.42; or any two R.sub.a and R.sub.b taken together with the carbon to which they are attached form a cycloalkyl or heterocyclyl; or R.sub.1 and any one of R.sub.a or R.sub.b taken together form heterocyclyl; R.sub.5 is R.sub.7, --(CH.sub.2).sub.m-L.sub.2-(CH.sub.2).sub.m--R.sub.7, or -(-L.sub.3-(CR.sub.aR.sub.b).sub.r--).sub.s-L.sub.3-R.sub.7; R.sub.6 is H, alkyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, heterocycloalkyl, any of which may be optionally singly or multiply substituted with R.sub.7 or --(CH.sub.2).sub.m-L.sub.2-(CH.sub.2).sub.m--R.sub.7; R.sub.7 is H, halo, alkyl, haloalkyl, perhaloalkyl, alkoxy, --OH, --OR.sub.8, --CN, --NR.sub.1R.sub.8, --(CR.sub.aR.sub.b).sub.mO(CR.sub.aR.sub.b).sub.mR.sub.8, --NR.sub.1(CR.sub.aR.sub.b).sub.mR.sub.8, --C(O)R.sub.8, --NR.sub.1(CR.sub.aR.sub.b).sub.mCOOH, --NR.sub.1C(O)R.sub.8, --C(O)NR.sub.1R.sub.8, --SR.sub.8, --S(O)R.sub.8, --S(O).sub.2R.sub.8, --S(O).sub.2NR.sub.1R.sub.8, --NR.sub.1S(O).sub.2R.sub.8; or a ring moiety selected from cycloalkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl, where such ring moiety is optionally singly or multiply substituted with halo, --OH, --CN, alkyl, alkoxy, haloalkyl or perhaloalkyl; each R.sub.8 is independently H, alkyl, cycloalkyl or aryl; L.sub.2 is independently, from the proximal to distal end of the structure of Formula I-R or I-S, null, --O--, --OC(O)--, --NR.sub.1--, --C(O)NR.sub.1--, --N(R.sub.1)--C(O)--, --S(O.sub.2)--, --C(O)-- or --S(O.sub.2)--N(R.sub.1)--; each L.sub.3 is independently null, --O--, or --N(R.sub.1)-- each m is independently 0, 1, 2, 3, 4, 5 or 6; each n is independently 0 or 1 or 2; p is 0, 1, 2 or 3; q is 0, 1, 2 or 3; each r is independently 2, 3, or 4; and each s is independently 1, 2, 3, or 4. 3. A method of treatment of a malcondition in a patient for which activation, potentiation, modulation or agonism of a glucagon-like peptide 1 receptor is medically indicated, comprising administering an effective amount of a compound having the structure of Formula I-R or I-S or a pharmaceutically acceptable isomer, enantiomer, racemate, salt, ester, prodrug, hydrate or solvate thereof: ##STR00529## wherein A is a 5-, 6- or 7-membered heteroaryl having one, two or three heteroatoms where each such heteroatom is independently selected from O, N, and S, and where any ring atom of such heteroaryl may be optionally substituted with one or more of R.sub.4; B is heterocyclyl or heterocyclylalkyl; C is aryl or arylalkyl; Y.sub.1 and Y.sub.2 are both null; Z is --C(O)--; each R.sub.1 is independently H or C.sub.1-4 alkyl; R.sub.2 is --O--R.sub.8, --N(R.sub.1)--SO.sub.2--R.sub.8, --NR.sub.41R.sub.42, --N(R.sub.1)--(CR.sub.aR.sub.b).sub.m--COOH, --N(R.sub.1)--(CR.sub.aR.sub.b).sub.m--CO--N(R.sub.1)-heterocyclyl, --N(R.sub.1)--(CR.sub.aR.sub.b).sub.m--CO--N(R.sub.1)(R.sub.7), or --N(R.sub.1)-heterocyclyl, wherein R.sub.2 is not --OH or --NH.sub.2; each R.sub.3 and R.sub.4 is independently H, halo, alkyl, alkyl substituted with R.sub.31, alkoxy, haloalkyl, perhaloalkyl, haloalkoxy, perhaloalkoxy, aryl, heterocyclyl, --OH, --OR.sub.8, --CN, --NO.sub.2, --NR.sub.1R.sub.8, --C(O)R.sub.8, --C(O)NR.sub.1R.sub.8, --NR.sub.1C(O)R.sub.8, --SR.sub.8, --S(O)R.sub.8, --S(O).sub.2R.sub.8, --OS(O).sub.2R.sub.8, --S(O).sub.2NR.sub.1R.sub.8, --NR.sub.1S(O).sub.2R.sub.8, --(CR.sub.aR.sub.b).sub.mNR.sub.1R.sub.8, --(CR.sub.aR.sub.b).sub.mO(CR.sub.aR.sub.b).sub.mR.sub.8, --(CR.sub.aR.sub.b).sub.mNR.sub.1(CR.sub.aR.sub.b).sub.mR.sub.8, or --(CR.sub.aR.sub.b).sub.mNR.sub.1(CR.sub.aR.sub.b).sub.mCOOH; or any two R.sub.3 or R.sub.4 groups on the same carbon atom taken together form oxo; each R.sub.31 is independently H, halo, hydroxyl, --NR.sub.41R.sub.42, or alkoxy; each R.sub.40 is independently H or alkyl; each R.sub.41 and R.sub.42 is independently R.sub.40 or --(CH.sub.2).sub.n--COO--R.sub.40, --C(O)--R.sub.40, aryl, heteroaryl, or two taken together with the N atom to which they are attached can form a 3- to 7-membered heterocyclyl; W.sub.1 is null or -L.sub.1-(CR.sub.aR.sub.b).sub.m-L.sub.1-R.sub.6; each L.sub.1 is independently, from the proximal to distal end of the structure of Formula I-R or I-S, null, --C(O)O--, --S(O.sub.2)--, --S--, --N(R.sub.1)--C(O)--N(R.sub.1)--, --N(R.sub.1)--C(O)--O--, --(O)-- or --S(O.sub.2)--NR.sub.1--; each R.sub.a and R.sub.b is independently H, alkyl, alkoxy, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl, any of which alkyl, alkoxy, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl may be optionally (singly or multiply) substituted with R.sub.7, or --(CH.sub.2).sub.mC(O)OR.sub.40, --(CH.sub.2).sub.mOR.sub.40, --(CH.sub.2).sub.mSR.sub.40, --(CH.sub.2).sub.mNR.sub.41R.sub.42, --(CH.sub.2).sub.mC(O)NR.sub.41R.sub.42; or any two R.sub.a and R.sub.b taken together with the carbon to which they are attached form a cycloalkyl or heterocyclyl; or R.sub.1 and any one of R.sub.a or R.sub.b taken together form heterocyclyl; R.sub.5 is R.sub.7, --(CH.sub.2).sub.m-L.sub.2-(CH.sub.2).sub.m--R.sub.7, or -(-L.sub.3-(CR.sub.aR.sub.b).sub.r--).sub.s-L.sub.3-R.sub.7; R.sub.6 is H, alkyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, heterocycloalkyl, any of which may be optionally singly or multiply substituted with R.sub.7 or --(CH.sub.2).sub.m-L.sub.2-(CH.sub.2).sub.m--R.sub.7; R.sub.7 is H, halo, alkyl, haloalkyl, perhaloalkyl, alkoxy, --OH, --OR.sub.8, --CN, --NR.sub.1R.sub.8, --(CR.sub.aR.sub.b).sub.mO(CR.sub.aR.sub.b).sub.mR.sub.8, --NR.sub.1(CR.sub.aR.sub.b).sub.mR.sub.8, --C(O)R.sub.8, --NR.sub.1(CR.sub.aR.sub.b).sub.mCOOH, --NR.sub.1C(O)R.sub.8, --C(O)NR.sub.1R.sub.8, --SR.sub.8, --S(O).sub.2R.sub.8, --S(O).sub.2R.sub.8, --S(O).sub.2NR.sub.1R.sub.8, --NR.sub.1S(O).sub.2R.sub.8; or a ring moiety selected from cycloalkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl, where such ring moiety is optionally singly or multiply substituted with halo, --OH, --CN, alkyl, alkoxy, haloalkyl or perhaloalkyl; each R.sub.8 is independently H, alkyl, cycloalkyl or aryl; L.sub.2 is independently, from the proximal to distal end of the structure of Formula I-R or I-S, null, --O--, --OC(O)--, --NR.sub.1--, --C(O)NR.sub.1--, --N(R.sub.1)--C(O)--, --S(O.sub.2)--, --C(O)-- or --S(O).sub.2--N(R.sub.1)--; each L.sub.3 is independently null, --O--, or --N(R.sub.1)-- each m is independently 0, 1, 2, 3, 4, 5 or 6; each n is independently 0 or 1 or 2; p is 0, 1, 2 or 3; q is 0, 1, 2 or 3; each r is independently 2, 3, or 4; and each s is independently 1, 2, 3, or 4 to the patient at a frequency and for a duration of time sufficient to provide a beneficial effect to the patient. 4. The method of claim 3 wherein the malcondition is type I diabetes, type II diabetes, or gestational diabetes. 5. The method of claim 3 wherein the malcondition is type I diabetes or type II diabetes. 6. The method of claim 3 wherein the malcondition is obesity, excessive appetite, insufficient satiety, or metabolic disorder. 7. The method of any one of claims 1-5 wherein A is a 5- or 6-membered heteroaryl group. 8. The method of claim 7 wherein the compound has the following structure: ##STR00530## ##STR00531## ##STR00532## ##STR00533## ##STR00534## ##STR00535## 9. The method of any one of claims 1-5 wherein C is aryl. 10. The method of claim 9 wherein the compound has the following structure: ##STR00536## 11. The method of any one of claims 1-5 wherein B is heterocyclyl. 12. The method of claim 11 wherein the compound has the following structure: ##STR00537## ##STR00538## ##STR00539## 13. The method of any one of claims 1-5 wherein the compound is administered in combination with a second medicament. 14. The method of claim 13 wherein the second medicament is an agonist or modulator for glucagon receptor, GIP receptor, GLP-2 receptor, or PTH receptor, or glucagon-like peptide 1 (GLP-1) receptor. 15. The method of claim 13 wherein the second medicament is exenatide, liraglutide, taspoglutide, albiglutide, or lixisenatide. 16. The method of claim 13 wherein the second medicament is a DPPIV inhibitor.

Details for Patent 9,187,522

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Glaxosmithkline Llc	TANZEUM	albiglutide	For Injection	125431	04/15/2014		2039-02-26
Sanofi-aventis U.s. Llc	ADLYXIN	lixisenatide	Injection	208471	07/27/2016		2039-02-26